Trial
NCT03150056
Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
GlaxoSmithKline
Collaborators
—
Condition
Solid Tumours
Intervention
GSK525762
Why stopped
This study has been terminated due to meeting protocol defined futility.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-08-10